The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.
about
Dose-finding based on bivariate efficacy-toxicity outcome using Archimedean CopulaSeamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.Phase I/II adaptive design for drug combination oncology trialsContinual Reassessment and Related Dose-Finding DesignsUsing Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes.Dose finding with longitudinal data: simpler models, richer outcomes.A Phase I/II trial design when response is unobserved in subjects with dose-limiting toxicityUtility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trialsDrug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic orderingChoice of designs and doses for early phase trials.Bayesian hybrid dose-finding design in phase I oncology clinical trials.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemA statistical evaluation of dose expansion cohorts in phase I clinical trials.Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.Innovations for phase I dose-finding designs in pediatric oncology clinical trials.Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.A robust Bayesian dose-finding design for phase I/II clinical trials.Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges.Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials.Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.Implementing the EffTox dose-finding design in the Matchpoint trial.An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.Novel dose-finding designs and considerations on practical implementations in oncology clinical trials.Sequential designs for individualized dosing in phase I cancer clinical trials.Response-adaptive clinical trials: case studies in the medical literature.Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies.Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.A Bayesian adaptive phase I-II trial design for optimizing the schedule of therapeutic cancer vaccines.Simple benchmark for complex dose finding studies.Robust EM Continual Reassessment Method in Oncology Dose FindingA comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.Optimizing the concentration and bolus of a drug delivered by continuous infusion.TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology
P2860
Q28535032-7D09CBAF-9BBC-4E79-BD77-C97E6405EB43Q30371414-3981EED5-6E7A-4D20-977B-B7260E7455BFQ30409168-3136DA74-7FDF-4855-AB8E-C6786C8F0B41Q30431500-AE9BE60C-578D-48F4-A0D7-DD7FC135DF4AQ30868533-5E9DCEF3-83A8-44C5-9C4E-1CE703CF88AFQ30976631-6E6A993F-20EF-437E-8B4D-EE4092DA81C7Q33894123-2C280372-AD35-4859-B328-EC071FA0BAC3Q33945668-67AC89BA-88F0-4CF5-936A-7D46CF5312F1Q34535243-622A89F1-BDC4-42BE-A0C5-4B2B1CE1CFBAQ34799578-E0459BD4-2794-42F1-86E9-B23130939FD9Q35147308-FF69394C-156A-4061-8C3A-5A3B42F2096BQ35175343-732E7FDC-E3F1-4356-AD39-A366B24DA911Q35775310-1867D786-0D3F-4E16-BA49-D307FEC5D490Q35776323-CAA968A8-895C-487A-9C08-FDE88F5C6720Q35797280-D54D7F8A-C56D-4B23-A563-9B3425DB0FA1Q36047412-8DB9F44E-0F08-4137-A9F6-A1B911DAE1DDQ36621967-EF52F159-7608-40D2-A8C1-63D1943FEBF7Q36757843-B456BE6A-B9E6-422F-A2B0-3C30DCEB0C03Q36913166-6A94DB1F-F24A-467A-B61D-83BED0FB8BCBQ37220245-CB24C2B5-D209-4764-97AA-3DAF1A0233CDQ37523183-795FA9D2-824D-4BD5-AC2D-2EA14BAA4696Q37552670-48EA0252-1977-4EE6-A2D4-34625A4C2FD2Q37737198-1FBB90D0-D759-446B-8F2E-36811E474B2FQ37841138-DA6775FB-F7A3-4CDB-962C-64D6C7937645Q38428895-CC2C5124-CAFA-4625-867F-C3D84FCBA55FQ38608632-8987A4E6-1921-4E77-B4EA-6CF7210938AFQ38654251-812D4D36-EB79-4BE8-B02F-ACB4F2353422Q38735192-5AEE60C0-3D4A-444E-9A50-88D9E0CBEC36Q38735952-3B916792-FA8D-4F2A-AAD9-BF33386754FBQ38824605-54A851A4-9BB5-4BE1-8524-7D86F14586A5Q39300281-F8A9554D-A957-45FA-A811-CCD422908DCDQ39374749-4C295006-F934-4E03-9438-F99344676F3DQ39909564-43D6D18D-4DE9-47AD-B4F9-3769FFDB776FQ40415839-F083162B-8BC4-4C90-9338-F908A9C8A62FQ40613557-EC4A4D45-941A-45F7-8A08-A3CDE8EE1C09Q40819161-84553664-A1A1-4407-853D-C20A091E3DBEQ41545765-60300471-2246-487D-9467-686061067A7AQ41790792-2F03D917-090C-41D7-81DF-DC6CFADD5CD9Q41978664-87C8F5E2-60FF-43AB-A106-430C741911E9Q42108875-962960AD-6A09-44ED-83B7-5311CF52E036
P2860
The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The bivariate continual reasse ...... als of two competing outcomes.
@en
The bivariate continual reasse ...... als of two competing outcomes.
@nl
type
label
The bivariate continual reasse ...... als of two competing outcomes.
@en
The bivariate continual reasse ...... als of two competing outcomes.
@nl
prefLabel
The bivariate continual reasse ...... als of two competing outcomes.
@en
The bivariate continual reasse ...... als of two competing outcomes.
@nl
P1476
The bivariate continual reasse ...... als of two competing outcomes.
@en
P2093
Thomas M Braun
P304
P356
10.1016/S0197-2456(01)00205-7
P407
P577
2002-06-01T00:00:00Z